Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Postoperative chemoradiotherapy is the recommended standard therapy for patients with locally advanced rectal cancer. In recent years, encouraging results with preoperative radiotherapy have been reported. We compared preoperative chemoradiotherapy with postoperative chemoradiotherapy for locally advanced rectal cancer. METHODS: We randomly assigned patients with clinical stage T3 or T4 or node-positive disease to receive either preoperative or postoperative chemoradiotherapy. The preoperative treatment consisted of 5040 cGy delivered in fractions of 180 cGy per day, five days per week, and fluorouracil, given in a 120-hour continuous intravenous infusion at a dose of 1000 mg per square meter of body-surface area per day during the first and fifth weeks of radiotherapy. Surgery was performed six weeks after the completion of chemoradiotherapy. One month after surgery, four five-day cycles of fluorouracil (500 mg per square meter per day) were given. Chemoradiotherapy was identical in the postoperative-treatment group, except for the delivery of a boost of 540 cGy. The primary end point was overall survival. RESULTS: Four hundred twenty-one patients were randomly assigned to receive preoperative chemoradiotherapy and 402 patients to receive postoperative chemoradiotherapy. The overall five-year survival rates were 76 percent and 74 percent, respectively (P=0.80). The five-year cumulative incidence of local relapse was 6 percent for patients assigned to preoperative chemoradiotherapy and 13 percent in the postoperative-treatment group (P=0.006). Grade 3 or 4 acute toxic effects occurred in 27 percent of the patients in the preoperative-treatment group, as compared with 40 percent of the patients in the postoperative-treatment group (P=0.001); the corresponding rates of long-term toxic effects were 14 percent and 24 percent, respectively (P=0.01). CONCLUSIONS: Preoperative chemoradiotherapy, as compared with postoperative chemoradiotherapy, improved local control and was associated with reduced toxicity but did not improve overall survival.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Among the patients in whom abdominoperineal resection (APR) was considered necessary at the time of enrollment, the percentage of patients in whom sphincter preservation was possible was significantly higher in the preoperative chemoradiotherapy group [119].”
From Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2018) · cites this paper as [119]
In the citing paper
“there was no significant difference in the 5-year survival rate”
From Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2018) · cites this paper as [119]
In the citing paper
“but the local recurrence rate and incidence of grade 3 or higher adverse events were significantly lower in the preoperative chemoradiotherapy group.”
From Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2018) · cites this paper as [119]
Citations
Cites
Statistical Methods in Cancer Research
Breslow, N. E. (1980) · Cited by 7,332
Preoperative Radiotherapy Combined with Total Mesorectal Excision for Resectable Rectal Cancer
Kapiteijn, E., Marijnen, C. A. M., Nagtegaal, I. D., Putter, H., Steup, W. H., Wiggers, T., Rutten, H. J. T., Pahlman, L., Glimelius, B., van Krieken, J. H. J. M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010580 · Cited by 4,205
Improved Survival with Preoperative Radiotherapy in Resectable Rectal Cancer
(1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361402 · Cited by 2,517
Effective Surgical Adjuvant Therapy for High-Risk Rectal Carcinoma
Krook, J. E., Moertel, C. G., Gunderson, L. L., Wieand, H. S., Collins, R. T., Beart, R. W., Kubista, T. P., Poon, M. A., Meyers, W. C., Mailliard, J. A., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199103143241101 · Cited by 1,879
Statistical methods in cancer research. Vol. 1. The analysis of case-control studies
(1983) · Food and Chemical Toxicology · doi:10.1016/0278-6915(83)90281-8 · Cited by 1,716
Prolongation of the Disease-Free Interval in Surgically Treated Rectal Carcinoma
Gastrointestinal Tumor Study Group (1985) · New England Journal of Medicine · doi:10.1056/nejm198506063122301 · Cited by 1,130
(2001) · The Lancet · doi:10.1016/s0140-6736(01)06409-1 · Cited by 870
Preoperative Radiotherapy for Resectable Rectal Cancer: A Meta-analysis
Cammà, C., Giunta, M., Fiorica, F., Pagliaro, L., Craxì, A., & Cottone, M. (2000) · JAMA · doi:10.1001/jama.284.8.1008 · Cited by 754
NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer
(1990) · JAMA · doi:10.1001/jama.264.11.1444 · Cited by 394
Hyams, D. M., Mamounas, E. P., Petrelli, N., Rockette, H., Jones, J., Wieand, S. H., Deutsch, M., Wickerham, L. D., Fisher, B., & Wolmark, N. (1997) · Diseases of the Colon & Rectum · doi:10.1007/bf02054976 · Cited by 360
Research works printed but not linked: 3
- Seegenschmiedt MH, 1993, Strahlenther Onkol, 169, 83
- Pichlmaier H, 1994, Chirurg, 65, 411
- Hermanek P. What can the pathologist tell the surgeon about rectal cancer resection? In: Scholefield JH, ed. Challenges in colorectal cancer. Oxford, England: Blackwell, 2000:81-90.
Cited by
Items 401–500 of 1,004
Xiao, W., Chen, G., Gao, Y., Lin, J., Wu, X., Luo, H.-L., Lu, Z., Wang, Q., Sun, R., Cai, P., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.07.004 · Cited by 107
Advances in the management of colorectal cancer: from biology to treatment
Ahmed, S., JOHNSON, K., Ahmed, O., & Iqbal, N. (2014) · International Journal of Colorectal Disease · doi:10.1007/s00384-014-1928-5 · Cited by 116
“Several randomized trials were performed to determine the optimal sequence of surgery and chemoradiotherapy and compared preoperative concurrent chemoradiation with postoperative 5-FU-based chemoradiotherapy [73–75].”
Kim, J. C., Kim, H. C., Yu, C. S., Han, K. R., Kim, J. R., Lee, K. H., Jang, S. J., Lee, S. S., & Ha, H. K. (2006) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2006.01.054 · Cited by 104
Chand, M., Bhangu, A. A., Wotherspoon, A. C., Stamp, G., Swift, R. I., Chau, I., Tekkis, P. P., & Brown, G. M. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu029 · Cited by 104
“It is important to note that the use of neoadjuvant treatment did not affect DFS which is consistent with previous reports [14, 15].”
ResultRestaging Locally Advanced Rectal Cancer with MR Imaging after Chemoradiation Therapy
Barbaro, B., Vitale, R., Leccisotti, L., Vecchio, F. M., Santoro, L., Valentini, V., Coco, C., Pacelli, F., Crucitti, A., Persiani, R., et al. (2010) · Radiographics · doi:10.1148/rg.303095085 · Cited by 104
Nair, R. M., Siegel, E. M., Chen, D., Fulp, W. J., Yeatman, T. J., Malafa, M. P., Marcet, J. E., & Shibata, D. (2008) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-008-0647-z · Cited by 103
Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Glimelius, B. L. G., Påhlman, L., & Cervantes, A. M. R. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq170 · Cited by 124
Leibold, T., Shia, J., Ruo, L., Minsky, B. D., Akhurst, T., Gollub, M. J., Ginsberg, M. S., Larson, S. M., Riedel, E., Wong, W. D., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.7704 · Cited by 103
den Dulk, M., Krijnen, P., Marijnen, C. A. M., Rutten, H. J. T., van de Poll-Franse, L. V., Putter, H., Kranenbarg, E. M., Jansen-Landheer, M. L. E. A., Coebergh, J. W. W., & van de Velde, C. J. �. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.05.004 · Cited by 112
Smith, R. K., Fry, R. D., Mahmoud, N. N., & Paulson, E. C. (2015) · International Journal of Colorectal Disease · doi:10.1007/s00384-015-2165-2 · Cited by 105
Engelen, S. M. E., Maas, M., Lahaye, M. J., Leijtens, J. W. A., van Berlo, C. L. H., Jansen, R. L. H., Breukink, S. O., Dejong, C. H. C., van de Velde, C. J. �., Beets‐Tan, R. G. H., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.03.006 · Cited by 106
KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy
Gaedcke, J., Grade, M., Jung, K., Schirmer, M., Jo, P., Obermeyer, C., Wolff, H. A., Herrmann, M. K. A., Beißbarth, T., Becker, H., et al. (2009) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2009.10.001 · Cited by 110
“Selection of patients, study design and treatment All 94 patients were enrolled in the CAO/ARO/AIO-94 [13] or CAO/ARO/AIO-04 (EudraCT-Number: 2006-002385-20) [14] trial of the German Rectal Cancer Study Group; 64 were males and 30 were females with a median age of 62.3 years (range: 35– 81 years).”
InfluentialBonnetain, F., Bosset, J. F., Gérard, J., Calais, G., Conroy, T., Mineur, L., Bouché, O., Maingon, P., Chapet, O., Radošević-Jelić, L., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.03.016 · Cited by 112
Brændengen, M., Tveit, K. M., Bruheim, K., Cvancarova, M., Berglund, Å., & Glimelius, B. L. G. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.07.007 · Cited by 107
Tato-Costa, J., Casimiro, S., Pacheco, T. R., Pires, R., Fernandes, A., Alho, I., Pereira, P., Costa, P., Castelo, H. B., Ferreira, J. A., et al. (2015) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2015.09.003 · Cited by 126
“Tumor recurrence after preoperative CRT followed by surgery with curative intent remains a major problem to successful cancer treatment, affecting 15% to 20% of patients diagnosed with locally advanced rectal cancer.(1,2) Tumor regression after neoadjuvant CRT has been used to evaluate the treatment response and progn…”
BackgroundGuillem, J. G., Ruby, J. A., Leibold, T., Akhurst, T., YEUNG, H. W. D., Gollub, M. J., Ginsberg, M. S., Shia, J., Suriawinata, A. A., Riedel, E., et al. (2012) · Annals of Surgery · doi:10.1097/sla.0b013e318277b625 · Cited by 117
“uT4 1 (1) Pre-CRT ERUS N stage (N = 113) uN0 22 (19)”
Azria, D., Doyen, J., Jarlier, M., Martel‐Lafay, I., Hennequin, C., Etienne, P.-L., Vendrely, V., François, É., Roche, G., Bouché, O., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx351 · Cited by 105
Outcome measures in multimodal rectal cancer trials
Fokas, E., Glynne‐Jones, R., Appelt, A. L., Beets‐Tan, R. G. H., Beets, G. L., Haustermans, K. M., Marijnen, C. A. M., Minsky, B. D., Ludmir, E. B., Quirke, P., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30024-3 · Cited by 107
Self-citationOrtholan, C., Romestaing, P., Chapet, O., & Gérard, J. P. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2011.12.002 · Cited by 107
Cancer-associated fibroblasts correlate with poor prognosis in rectal cancer after chemoradiotherapy
Saigusa (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.906 · Cited by 100
Intven, M., Reerink, O., & Philippens, M. E. P. (2014) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.24718 · Cited by 100
“From treatment with surgery alone it changed to a multidisciplinary treatment combining chemotherapy, radiotherapy and surgery (1,2).”
BackgroundNeoadjuvant Bevacizumab, Oxaliplatin, 5-Fluorouracil, and Radiation for Rectal Cancer
DiPetrillo, T. A., Pricolo, V. E., Lagares-García, J. A., Vrees, M. D., Klipfel, A. A., Cataldo, T., Sikov, W. M., McNulty, B., Shipley, J., Anderson, E., et al. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.08.005 · Cited by 106
Accuracy of MRI in Restaging Locally Advanced Rectal Cancer After Preoperative Chemoradiation
van den Broek, J. J., van der Wolf, F. S. W., Lahaye, M. J., Heijnen, L. A., Meischl, C., Heitbrink, M. A., & Schreurs, W. H. (2017) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000000743 · Cited by 101
Fokas, E., Fietkau, R., Hartmann, A., Hohenberger, W., Grützmann, R., Ghadimi, M. B., Liersch, T., Ströbel, P., Grabenbauer, G. G., Graeven, U., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy143 · Cited by 101
Self-citationWillett, C. G., Kozin, S. V., Duda, D. G., di Tomaso, E., Kozak, K. R., Boucher, Y., & Jain, R. K. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.08.007 · Cited by 100
Presurgical Chemotherapy in Patients Being Considered for Liver Resection
Kemeny, N. E. (2007) · The Oncologist · doi:10.1634/theoncologist.12-7-825 · Cited by 105
Effect of multidisciplinary team treatment on outcomes of patients with gastrointestinal malignancy
Du, C. (2011) · World Journal of Gastroenterology · doi:10.3748/wjg.v17.i15.2013 · Cited by 109
Kosinski, L. A., Habr‐Gama, A., Ludwig, K., & Perez, R. O. (2012) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21138 · Cited by 121
Kanemitsu, Y., Komori, K., Shida, D., Ochiai, H., Tsukamoto, S., Kinoshita, T., & Moriya, Y. (2017) · Surgery · doi:10.1016/j.surg.2017.02.005 · Cited by 99
Ryan, É. J., O'Sullivan, D. P., Kelly, M. E., Syed, A. Z., Neary, P. C., O’Connell, P. R., Kavanagh, D. O., Winter, D. C., & O’Riordan, J. M. (2019) · British journal of surgery · doi:10.1002/bjs.11220 · Cited by 102
Multidisciplinary Management of Rectal Cancer: the OSTRICH
Dietz, D. W. (2013) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-013-2276-4 · Cited by 104
Patient and Physician Preferences for Surgical and Adjuvant Treatment Options for Rectal Cancer
Harrison, J. D., Solomon, M. J., Young, J. M., Meagher, A., Butow, P., Salkeld, G., Hruby, G., & Clarke, S. (2008) · Archives of Surgery · doi:10.1001/archsurg.143.4.389 · Cited by 100
Gunnlaugsson, A., Kjellén, E., Nilsson, P. G., Bendahl, P., Willner, J., & Johnsson, A. (2007) · Acta Oncologica · doi:10.1080/02841860701317873 · Cited by 103
“the cases in 5-FU based chemoradiotherapy [1,2,9,10], and is slightly more frequent than with”
BackgroundSerum CEA as a predictor for the response to preoperative chemoradiation in rectal cancer
Park, Y.-A., Sohn, S. K., Seong, J., Baik, S. H., Lee, K.-Y., Kim, N. K., & Cho, C.-W. (2006) · Journal of Surgical Oncology · doi:10.1002/jso.20320 · Cited by 101
Schmoll, H., Stein, A., Cutsem, E. V., Price, T. J., Hofheinz, R., Nordlinger, B., Daisne, J., Janssens, J., Brenner, B., Reinel, H. H., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01740 · Cited by 111
Pizzi, A. D., Chiarelli, A. M., Chiacchiaretta, P., d’Annibale, M., Croce, P., Rosa, C., Mastrodicasa, D., Trebeschi, S., Lambregts, D. M. J., Caposiena, D., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-84816-3 · Cited by 104
Neoadjuvant treatment of colorectal cancer: comprehensive review
Smith, H. G., Nilsson, P. J., Shogan, B. D., Harji, D. P., Gambacorta, M. A., Romano, Â., Brandl, A., & Qvortrup, C. (2024) · BJS Open · doi:10.1093/bjsopen/zrae038 · Cited by 114
“However, poor compliance with postoperative chemotherapy has been a persistent issue 10,12 .”
BackgroundPatterns of Colorectal Cancer Care in the United States: 1990–2010
Murphy, C. C., Harlan, L. C., Lund, J. L., Lynch, C. F., & Geiger, A. M. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv198 · Cited by 109
“These changes parallel results of the landmark German trial published in 2004 (15) that showed preoperative chemoradiation decreased the risk of local recurrence, improved sphincter preservation, and decreased treatment-related toxicities compared with postoperative therapy.”
ResultShen, L., Zhang, H., Liang, L., Li, G., Fan, M., Wu, Y., Zhu, J. Y., & Zhang, Z. (2014) · Radiation Oncology · doi:10.1186/s13014-014-0295-2 · Cited by 103
Horch, R. E., Hohenberger, W., Eweida, A. M., Kneser, U., Weber, K., Arkudas, A., Merkel, S., Göhl, J., & Beier, J. P. (2014) · International Journal of Colorectal Disease · doi:10.1007/s00384-014-1868-0 · Cited by 98
Self-citationMaking sense of adjuvant chemotherapy in colorectal cancer
Chan, G. H. J., & Chee, C. E. (2019) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2019.06.03 · Cited by 82
HDAC Inhibitor, Valproic Acid, Induces p53-Dependent Radiosensitization of Colon Cancer Cells
Chen, X., Wong, P. W., Radany, E. H., & Wong, J. Y. C. (2009) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2009.0629 · Cited by 105
Hohenberger, W., Merkel, S., Matzel, K. E., Bittorf, B. R., Papadopoulos, T. G., & Göhl, J. (2005) · Colorectal Disease · doi:10.1111/j.1463-1318.2005.00839.x · Cited by 99
Self-citationCronin, D., Harlan, L. C., Potosky, A. L., Clegg, L. X., Stevens, J. L., & Mooney, M. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00775.x · Cited by 98
Perrakis, A., Weber, K., Merkel, S., Matzel, K. E., Agaimy, A., Gebbert, C., & Hohenberger, W. (2014) · International Journal of Colorectal Disease · doi:10.1007/s00384-014-1971-2 · Cited by 100
“This led to the introduction and acceptance of an interdisciplinary therapeutic algorithm including TME and neoadjuvant chemoradiation in locally advanced cases, as state of art [5–9, 22–25].”
BackgroundSelf-citationRisk factors for permanent stoma after rectal cancer surgery with temporary ileostomy
Kim, M. J., Kim, Y. S., Park, S. C., Sohn, D. K., Kim, D. Y., Chang, H. J., & Oh, J. H. (2015) · Surgery · doi:10.1016/j.surg.2015.09.011 · Cited by 97
Pucciarelli, S., Bianco, P. D., Efficace, F., Serpentini, S., Capirci, C., Paoli, A. D., Amato, A., Cuicchi, D., & Nitti, D. (2010) · Annals of Surgery · doi:10.1097/sla.0b013e3181fcb856 · Cited by 109
“Use of anti-diarrhea drugs (yes) 2 (1) 9 (7) 7 (9) 8 (10) 0.”
Habr‐Gama, A., Perez, R. O., Proscurshim, I., Rawet, V., Pereira, D. D., Sousa, A. H. S. E., Kiss, D. R., & Cecconello, I. (2008) · Diseases of the Colon & Rectum · doi:10.1007/s10350-007-9148-5 · Cited by 97
“This neoadjuvant chemoradiation therapy (CRT) approach has resulted in decreased toxicity rates, improved local disease control, and significant tumor downstaging.(6) This latter effect is observed by objective primary tumor regression (ypT), complete pathologic response (ypT0N0), decreased rates of Stage III disease,…”
BackgroundBujko, K., Nowacki, M. P., Nasierowska-Guttmejer, A. M., Kępka, L., Winkler-Spytkowska, B., Suwiński, R., Olędzki, J., Stryczyńska, G., Wieczorek, A., Serkies, K., et al. (2005) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2005.04.004 · Cited by 96
“local failure and less toxic than postoperative radio(chemo)therapy [9,28].”
BackgroundPatterns of local recurrence in rectal cancer after a multidisciplinary approach
Enríquez-Navascués, J. M., Borda, N., Lizerazu, A., Placer, C., Elosegui, J. L., Ciria, J. P., Lacasta, A., & Bujanda, L. (2011) · World Journal of Gastroenterology · doi:10.3748/wjg.v17.i13.1674 · Cited by 105
Markovina, S. T., Youssef, F. F., Roy, A., Aggarwal, S., Khwaja, S. S., DeWees, T. A., Tan, B. R., Hunt, S. R., Myerson, R. J., Chang, D. T., et al. (2017) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2017.05.048 · Cited by 99
The current landscape of locally advanced rectal cancer
Aklilu, M., & Eng, C. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.118 · Cited by 104
Memon, S., Lynch, A. C., Bressel, M., WISE, A. G., & Heriot, A. G. (2015) · Colorectal Disease · doi:10.1111/codi.12976 · Cited by 100
Birgisson, H., Påhlman, L., Gunnarsson, U., & Glimelius, B. L. G. (2007) · British journal of surgery · doi:10.1002/bjs.5918 · Cited by 100
Duda, D. G., Willett, C. G., Ancukiewicz, M., Tomaso, E., Shah, M., Czito, B. G., Bentley, R., Poleski, M., Lauwers, G. Y., Carroll, M., et al. (2010) · The Oncologist · doi:10.1634/theoncologist.2010-0029 · Cited by 94
Design of Clinical Trials of Radiation Combined with Antiangiogenic Therapy
Senan, S., & Smit, E. F. (2007) · The Oncologist · doi:10.1634/theoncologist.12-4-465 · Cited by 98
CHEMORADIOTHERAPY FOR COLORECTAL CANCER
Andre, N., & Schmiegel, W. (2005) · Gut · doi:10.1136/gut.2004.062745 · Cited by 109
Bowel dysfunction after treatment for rectal cancer
Emmertsen, K. J., & Laurberg, S. (2008) · Acta Oncologica · doi:10.1080/02841860802195251 · Cited by 105
“Randomised trials have shown that preoperative radiotherapy decreases local recurrence rates more than postoperative irradiation while also decreasing the side effects [2,19].”
BackgroundKupsch, J., Jackisch, T., Matzel, K. E., Zimmer, J., Schreiber, A., Sims, A., Witzigmann, H., & Stelzner, S. (2018) · International Journal of Colorectal Disease · doi:10.1007/s00384-018-3006-x · Cited by 103
Liu, L., Zhang, Z., Zhou, L., Hu, L., Yin, C., Qing, D., Huang, S., Cai, X., & Chen, Y. (2020) · Experimental Cell Research · doi:10.1016/j.yexcr.2020.111956 · Cited by 94
Sassen, S., de Booij, M., Sosef, M. N., Berendsen, R. C. M., Lammering, G., Clarijs, R., Bakker, M., Beets‐Tan, R. G. H., Warmerdam, F. A. R. M., & Vliegen, R. F. A. (2013) · European Radiology · doi:10.1007/s00330-013-2956-1 · Cited by 101
“The application of neoadjuvant chemo- and radiation therapy combinedwith optimised surgical techniques has tremendously improved local control of rectal cancer [1, 2].”
BackgroundJanssen, M. H. M., Öllers, M., Riedl, R. G., van den Bogaard, J., Buijsen, J., van Stiphout, R. G. P. M., Aerts, H. J. W. L., Lambin, P., & Lammering, G. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.04.030 · Cited by 96
Integration of Novel Agents into Combined-Modality Treatment for Rectal Cancer Patients
Rödel, C. M., & Sauer, R. (2007) · Strahlentherapie und Onkologie · doi:10.1007/s00066-007-9000-9 · Cited by 100
“recent large phase III trials of preoperative 5-FU CRT plus postoperative 5-FU CT (the EORTC 22921, the FFCD 9203, and our German CAO/ARO/AIO-94 trial), a total of 25%, 23%, and 20%, respectively, did not start postoperative CT [6, 25, 64].”
BackgroundSelf-citationMRI Evaluation of the Response of Rectal Cancer to Neoadjuvant Chemoradiation Therapy
Kalisz, K. R., Enzerra, M. D., & Paspulati, R. M. (2019) · Radiographics · doi:10.1148/rg.2019180075 · Cited by 93
Sebag‐Montefiore, D., Glynne‐Jones, R., Falk, S., Meadows, H. M., & Maughan, T. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602818 · Cited by 93
Hofheinz, R., Horisberger, K., Woernle, C. M., Wenz, F. K., Kraus-Tiefenbacher, U., Kähler, G. F. B. A., Dinter, D. J., Grobholz, R., Heeger, S., Post, S., et al. (2006) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2006.07.005 · Cited by 96
Intven, M., Reerink, O., & Philippens, M. E. P. (2012) · Strahlentherapie und Onkologie · doi:10.1007/s00066-012-0270-5 · Cited by 106
Kim, T. H., Chang, H. J., Kim, D. Y., Jung, K. H., Hong, Y. S., Kim, S. Y., Park, J. W., Oh, J. H., Lim, S., Choi, H. S., et al. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.06.019 · Cited by 92
Radiotherapy for Colorectal Cancer: Current Standards and Future Perspectives
Häfner, M. F., & Debus, J. (2016) · Visceral Medicine · doi:10.1159/000446486 · Cited by 116
de Lacy, F. B., van Laarhoven, J. J. E. M., Pena, R., Arroyave, M. C., Bravo, R., Cuatrecasas, M., & Lacy, A. M. (2017) · Surgical Endoscopy · doi:10.1007/s00464-017-5944-8 · Cited by 95
Ferrari, R., Mancini-Terracciano, C., Voena, C., Rengo, M., Zerunian, M., Ciardiello, A., Grasso, S., Marè, V., Paramatti, R., Russomando, A., et al. (2019) · European Journal of Radiology · doi:10.1016/j.ejrad.2019.06.013 · Cited by 94
Dijkstra, E. A., Hospers, G. A. P., Kranenbarg, E. M., Fleer, J., Roodvoets, A. G. H., Bahadoer, R. R., Guren, M. G., Tjalma, J. J. J., Putter, H., Crolla, R. M. P. H., et al. (2022) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2022.04.013 · Cited by 92
Mei, W.-J., Wang, X., Li, Y., Sun, Y., Yang, C., Lin, J., Wu, Z., Zhang, R., Wang, W., Li, Y., et al. (2022) · Annals of Surgery · doi:10.1097/sla.0000000000005780 · Cited by 98
“Age, years Median(range) 60 (31-75) 60 (28-75) Sex Male 188 (62·7) 177 (61·2) Female 112 (37·3) 112 (38·8) Clinical T category cT2 16 (5·3) 11 (3·8) cT3 201 (67·0) 202 (69·9) cT4a 83 (27·7) 76 (26·3) Clinical N category cN0 92 (30·7) 77 (26·7) cN1 147 (49·0) 133 (46·0) cN2 61 (20·3) 79 (27·3) Distance from the anal ve…”
“Fast-track” rehabilitation after rectal cancer resection
Schwenk, W., Neudecker, J., Raué, W., Haase, O., & Müller, J. M. (2005) · International Journal of Colorectal Disease · doi:10.1007/s00384-005-0056-7 · Cited by 92
“utilising “traditional” perioperative care [4, 6, 7, 21].”
Pelvic Exenteration Affords Safe and Durable Treatment for Locally Advanced Rectal Carcinoma
Gannon, C. J., Zager, J. S., Chang, G. J., Feig, B. W., Wood, C. G., Skibber, J. M., & Rodrı́guez-Bigas, M. A. (2007) · Annals of Surgical Oncology · doi:10.1245/s10434-007-9385-9 · Cited by 92
Bijelić, L., Kumar, A. S., Stuart, O. A., & Sugarbaker, P. H. (2012) · Gastroenterology Research and Practice · doi:10.1155/2012/163284 · Cited by 95
Local staging of rectal cancer: A review of imaging
Beets‐Tan, R. G. H., & Beets, G. L. (2011) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.22475 · Cited by 91
“In 2004 a trial convincingly showed that chemoradiation is better administered preoperatively than postoperatively, and this gradually led to a change in practice (6).”
BackgroundNeoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer
Habermehl, D., Kessel, K. A., Welzel, T., Hof, H., Abdollahi, A., Bergmann, F., Rieken, S., Weitz, J., Werner, J., Schirmacher, P., et al. (2012) · Radiation Oncology · doi:10.1186/1748-717x-7-28 · Cited by 91
“Neoadjuvant radiation combined with chemotherapy has been proven to be effective and to lead to substantial downstaging prior to surgery, associated with improved outcome, for several tumour entities [4,5,13-17].”
BackgroundSTAT3: A Novel Molecular Mediator of Resistance to Chemoradiotherapy
Spitzner, M., Ebner, R., Wolff, H., Ghadimi, B., Wienands, J., & Grade, M. (2014) · Cancers · doi:10.3390/cancers6041986 · Cited by 90
“For locally advanced rectal cancer, the standard treatment consists of preoperative CRT, followed by radical surgical resection and postoperative chemotherapy [58–60].”
MethodCho, E. Y., Kim, S. H., Yoon, J.-H., Lee, Y., Lim, Y., Kim, S., Baek, H. J., & Eun, C. K. (2013) · European Journal of Radiology · doi:10.1016/j.ejrad.2013.08.007 · Cited by 94
“Although surgery s the most common curative treatment for rectal cancer, neoaduvant chemoradiation therapy (CRT) is considered the standard f care for locally advanced rectal cancer (LARC) because several tudies reported that neoadjuvant CRT could significantly decrease ts local recurrence rate [2,3].”
BackgroundAdequate Length of the Distal Resection Margin in Rectal Cancer: From the Oncological Point of View
Park, I. J., & Kim, J. C. (2010) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-010-1165-3 · Cited by 91
Organ Preservation for Rectal Cancer
Baxter, N. N., & García‐Aguilar, J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.7840 · Cited by 91
Colorectal cancer survival in the USA and Europe: a CONCORD high-resolution study
Allemani, C., Rachet, B., Weir, H. K., Richardson, L. C., Lepage, C., Faivre, J., Gatta, G., Capocaccia, R., Sant, M., Baili, P., et al. (2013) · BMJ Open · doi:10.1136/bmjopen-2013-003055 · Cited by 92
“31 We were unable to distinguish between the impact of preoperative and postoperative radiotherapy, because this information was not systematically available, but fewer patients received radiotherapy in Europe than in the USA and the practice in Europe was strikingly heterogeneous, even within a…”
ResultMok, H. Y. I., Crane, C. H., Palmer, M. B., Briere, T. M., Beddar, S. A., Delclos, M. E., Krishnan, S., & Das, P. (2011) · Radiation Oncology · doi:10.1186/1748-717x-6-63 · Cited by 94
“Indeed, acute grade 3 or higher gastrointestinal toxicity in the form of severe diarrhea was reported to be 12% by Sauer and colleagues [4], with modern series reporting rates as high as 29%[6].”
BackgroundAccuracy of Various Lymph Node Staging Criteria in Rectal Cancer with Magnetic Resonance Imaging
Gröne, J., Loch, F. N., Taupitz, M., Schmidt, C. G., & Kreis, M. E. (2017) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-017-3568-x · Cited by 96
U3-1402, a Novel HER3-Targeting Antibody-Drug Conjugate, for the Treatment of Colorectal Cancer
Koganemaru, S., Kuboki, Y., Koga, Y., Kojima, T., Yamauchi, M., Maeda, N., Kagari, T., Hirotani, K., Yasunaga, M., Matsumura, Y., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0452 · Cited by 90
“Therefore, HER3-targeted therapies have been developed (24, 25); however, monoclonal antibody against HER3, such as patritumab, or dualtarget monoclonal antibodies against EGFR/HER3, such as duligotuzumab, have not shown any significant clinical benefit in mCRC patients in early clinical trials (26, 27).”
BackgroundS3 Guidelines for Colorectal Carcinoma
Schmiegel, W., Pox, C. P., Reinacher-Schick, A. C., Adler, G., Arnold, D., Fleig, W. E., Fölsch, U. R., Frühmorgen, P., Graeven, U., Heinemann, V., et al. (2010) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0028-1109936 · Cited by 120
Self-citationGovindarajan, A., Gönen, M., Weiser, M. R., Shia, J., Temple, L. K. F., Guillem, J. G., Paty, P. B., & Nash, G. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.2235 · Cited by 90
Sineshaw, H. M., Jemal, A., Thomas, C. R., & Митин, Т. (2016) · Cancer · doi:10.1002/cncr.29993 · Cited by 97
Bouleuc, C., Anota, A., Cornet, C., Grodard, G., Thiery-Vuillemin, A., Dubroeucq, O., Crétineau, N., Frasie, V., Gamblin, V., Chvetzoff, G., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0856 · Cited by 102
Serra‐Aracil, X., Pericay, C., Closa, J. B., Golda, T., Biondo, S., Hernández, P., Targarona, E. M., Borda-Arrizabalaga, N., Reina, A., Delgado, S., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.09.160 · Cited by 96
Kinugasa, Y., Uehara, K., Yamaguchi, K., Saito, Y., Murofushi, K. N., Sugai, T., Ishiguro, M., Ishihara, S., Ueno, H., Oka, S., et al. (2025) · International Journal of Clinical Oncology · doi:10.1007/s10147-025-02899-8 · Cited by 112
Kim, D. Y., Jung, K. H., Kim, T. H., Kim, D., Chang, H. J., Jeong, J. Y., Kim, Y. H., Son, S.-H., Yun, T., Hong, C. W., et al. (2006) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2006.08.063 · Cited by 90
Parc, Y. R., Zutshi, M., Zalinski, S., Ruppert, R., Fürst, A., & Fazio, V. W. (2009) · Diseases of the Colon & Rectum · doi:10.1007/dcr.0b013e3181beb4d8 · Cited by 97
Dinnewitzer, A., Jäger, T., Nawara, C., Buchner, S., Hitzl, W., & Öfner, D. (2013) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0b013e31829ef472 · Cited by 90
Long-term outcomes and quality of life after rectal carcinoma surgery
Hörske, C., Weber, K., Goehl, J., Hohenberger, W., & Merkel, S. (2010) · British journal of surgery · doi:10.1002/bjs.7105 · Cited by 101
Self-citationKendziorra, E., Ahlborn, K., Spitzner, M., Rave‐Fränk, M., Emons, G., Gaedcke, J., Krämer, F., Wolff, H. A., Becker, H., Beißbarth, T., et al. (2011) · Carcinogenesis · doi:10.1093/carcin/bgr222 · Cited by 99
Tian, X., Nguyen, M., Foote, H. P., Caster, J. M., Roche, K. C., Peters, C. G., Wu, P., Jayaraman, L., Garmey, E. G., Tepper, J. E., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2951 · Cited by 96
“Several large randomized trials have demonstrated that 8-25% of patients receiving only CRT achieve a pathologic complete response (pCR) (7-13).”
Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer
Ceelen, W. P., Nieuwenhove, Y. V., & Fierens, K. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006041.pub2 · Cited by 127
High sacrectomy for locally recurrent rectal cancer: Can long‐term survival be achieved?
Dozois, E. J., Privitera, A., Holubar, S. D., Aldrete, J. F., Sim, F. H., Rose, P. S., Walsh, M. F., Bower, T. C., Leibovich, B. C., Nelson, H., et al. (2010) · Journal of Surgical Oncology · doi:10.1002/jso.21774 · Cited by 93
Metadata
- Authors
- Sauer, R., Becker, H., Hohenberger, W., Rödel, C., Wittekind, C., Fietkau, R., Martus, P., Tschmelitsch, J., Hager, E., Hess, C. F., Karstens, J.-H., Liersch, T., Schmidberger, H., & Raab, R.
- Affiliations
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Leipzig University (DE)
- University of Rostock (DE)
- Charité – Universitätsmedizin Berlin (DE)
- Hospital of the Brothers of St. John of God (AT)
- Klinikum Klagenfurt (AT)
- University of Göttingen (DE)
- Medizinische Hochschule Hannover (DE)
- Klinikum Oldenburg (DE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-10-21
- Volume
- 351
- Issue
- 17
- Pages
- 1731-1740
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2125452425
- Cited by
- 6,050
- References
- 19
- Citations by year
- 2026: 178 · 2025: 205 · 2024: 232 · 2023: 275 · 2022: 310 · 2021: 324 · 2020: 322 · 2019: 321 · 2018: 305 · 2017: 298 · 2016: 291 · 2015: 348 · 2014: 340 · 2013: 333 · 2012: 346
- FWCI
- 82.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- GRO (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Surgery › Colorectal and Anal Carcinomas
- Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
- Keywords
- rectal cancer, locally advanced rectal cancer, neoadjuvant chemoradiotherapy, postoperative chemoradiotherapy, neoadjuvant therapy, adjuvant therapy, 5-fluorouracil, boost radiotherapy, local recurrence, overall survival, treatment toxicity
- MeSH terms
- Adult, Aged, Antineoplastic Agents, Combined Modality Therapy, Female, Fluorouracil, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Postoperative Care, Postoperative Complications, Preoperative Care, Quality Control, Radiotherapy, Rectal Neoplasms, Incidence, Proportional Hazards Models, Survival Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.